

## FAU Antibody (N-term) Blocking peptide

Synthetic peptide Catalog # BP1600a

### **Specification**

## FAU Antibody (N-term) Blocking peptide - Product Information

Primary Accession

P35544

## FAU Antibody (N-term) Blocking peptide - Additional Information

#### **Other Names**

Ubiquitin-like protein FUBI, FAU

#### Target/Specificity

The synthetic peptide sequence used to generate the antibody <a href=/product/products/AP1600a>AP1600a</a> was selected from the N-term region of human FUBI. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

#### FAU Antibody (N-term) Blocking peptide - Protein Information

# FAU Antibody (N-term) Blocking peptide - Protocols


Provided below are standard protocols that you may find useful for product applications.

### • Blocking Peptides

FAU Antibody (N-term) Blocking peptide - Images

## FAU Antibody (N-term) Blocking peptide - Background

FUBI is the cellular homolog of the fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV). It is a fusion protein consisting of the ubiquitin-like protein fubi at the N terminus and ribosomal protein S30 at the C terminus. It has been proposed that the fusion protein is post-translationally processed to generate free fubi and free ribosomal protein S30. Fubi is a member of the ubiquitin family, and ribosomal protein S30 belongs to the S30E family of ribosomal proteins. Whereas the function of fubi is currently unknown, ribosomal protein S30 is a component





of the 40S subunit of the cytoplasmic ribosome.

## FAU Antibody (N-term) Blocking peptide - References

Rossman, T.G., et al., Oncogene 22(12):1817-1821 (2003).Kenmochi, N., et al., Genome Res. 8(5):509-523 (1998).Vladimirov, S.N., et al., Eur. J. Biochem. 239(1):144-149 (1996).Kas, K., et al., Genomics 17(2):387-392 (1993).Michiels, L., et al., Oncogene 8(9):2537-2546 (1993).